Chugai Pharma (United States)
In research, Chugai Pharma (United States) stands highest in Medicine (#9,080 of 10,443 worldwide) and Health Sciences (#10,902 of 11,982 worldwide), 2022–2025.
- World rank, 2022–2025
- #14,250 of 28,054 · #13,155 all time
- Rank in United States
- #1,989 of 4,192
- Research works
- 1.4k ▼ 22% vs 2013–17
- Citations
- 26k 18.7 per fractional work
- Top-10% rate
- 11.1% record average 16.5%
- Open access
- 57% world 28%
What is Chugai Pharma (United States) known for in research?
The fields where it stands highest, 2022–2025, ranked among every institution above the floor in each field.
| Field | World rank | Where that sits | Top-10% rate | Works | All time |
|---|---|---|---|---|---|
| MedicineField | #9,080 of 10,443 | 12.6% | 64 | #7237 | |
| Health SciencesDomain | #10,902 of 11,982 | 12.0% | 68 | #9488 |
Each strip is that field’s whole ranked pool, with the notch where Chugai Pharma (United States) sits in it, in the colour of the band that rank falls in. The track under the rate is the rate itself: it carries no world mark, because the world rate differs by field (from about 6% to 21% in this record).
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Veterinary, 6.4×. Every wedge is a field page.
- Veterinary 6.4×
- Immunology and Microbiology 5.0×
- Chemical Engineering 4.9×
- Pharmacology, Toxicology and Pharmaceutics 4.3×
- Biochemistry, Genetics and Molecular Biology 3.2×
- Medicine 2.6×
- Mathematics 2.1×
- Chemistry 2.0×
- Nursing 1.6×
- Economics, Econometrics and Finance 0.6×
- Neuroscience 0.5×
- Psychology 0.4×
- Materials Science 0.4×
- Decision Sciences 0.3×
- Health Professions 0.3×
- Computer Science 0.3×
- Environmental Science 0.3×
- Engineering 0.2×
- Earth and Planetary Sciences 0.2×
- Social Sciences 0.2×
- Physics and Astronomy 0.1×
- Agricultural and Biological Sciences 0.1×
Who are the top researchers at Chugai Pharma (United States)?
Ranked on the composite score, Masahiko Mihara, Yoshiyuki Ohsugi and Takehisa Kitazawa lead among researchers whose main affiliation is Chugai Pharma (United States).
- 1 Masahiko Mihara United States · #278,521 worldwide 117 citations · 18 works
- 2 Yoshiyuki Ohsugi United States · #341,675 worldwide 65 citations · 19 works
- 3 Takehisa Kitazawa United States · #343,873 worldwide 96 citations · 29 works
- 4 Tomoyuki Igawa United States · #450,548 worldwide 97 citations · 21 works
- 5 Noboru Kubodera United States · #460,848 worldwide 76 citations · 25 works
- 6 Yoshio Takagaki United States · #580,740 worldwide 60 citations · 15 works
- 7 Yoshihiro Nitta United States · #1,087,150 worldwide 43 citations · 43 works
- 8 Norio Shirakawa United States · #1,106,078 worldwide 7 citations · 16 works
- 9 Kazushige Sakai United States · #1,369,294 worldwide 39 citations · 26 works
- 10 Atsuhiko Kato United States · #1,380,079 worldwide 18 citations · 27 works
Which keywords describe research at Chugai Pharma (United States)?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Monoclonal Antibodies, Therapeutic Antibodies, Glycosylation, Antibody Engineering, Fc Receptors, Inflammation, Biopharmaceuticals and Immunotherapy.
- Prophylaxis
- Genomic Profiling
- PD-1 and PD-L1
- Monoclonal Antibody
- Tumor Regression
- Chimeric Antigen Receptor
- Peptide Synthesis
- PET Imaging
- Autoantibodies
- Pharmacokinetics
- Cancer Therapy
- Protein Aggregation
- Lymphoma
- Targeted Therapy
- Chemotherapy
- Immunogenicity
- Immunotherapy
- Fc Receptors
- Inflammation
- Therapeutic Antibodies
- Monoclonal Antibodies
- Glycosylation
- Antibody Engineering
- Biopharmaceuticals
- Cancer
- Drug Discovery
- Recombinant Proteins
- Clinical Trials
- Tumor Microenvironment
- Stability
- Cancer Immunotherapy
- Protein-Protein Interactions
- Angiogenesis
- Foldamers
- CAR T Cells
- Rituximab
- Molecular Docking
- Immune Checkpoint Blockade
- Gene Therapy
- Inhibitors
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Monoclonal Antibodies14▲ 126×3 topics
- Therapeutic Antibodies13▲ 144×2 topics
- Glycosylation11▲ 75×3 topics
- Inflammation10▲ 3.6×24 topics
- Antibody Engineering9▲ 126×1 topic
- Fc Receptors9▲ 126×1 topic
- Biopharmaceuticals6▲ 96×3 topics
- Immunotherapy6▲ 6.8×13 topics
- Cancer6▲ 3.4×20 topics
- Immunogenicity6▲ 102×2 topics
- Drug Discovery5▲ 19×4 topics
- Chemotherapy5▲ 5.3×9 topics
- Recombinant Proteins5▲ 117×2 topics
- Targeted Therapy5▲ 16×4 topics
- Clinical Trials4▲ 5.2×6 topics
- Lymphoma4▲ 21×2 topics
- Tumor Microenvironment4▲ 7.6×7 topics
- Protein Aggregation4▲ 60×1 topic
- Stability4▲ 14×1 topic
- Cancer Therapy4▲ 5.0×8 topics
- Cancer Immunotherapy4▲ 18×2 topics
- Pharmacokinetics4▲ 11×6 topics
- Protein-Protein Interactions3▲ 57×2 topics
- Autoantibodies3▲ 10×7 topics
- Angiogenesis3▲ 7.2×7 topics
- PET Imaging3▲ 14×3 topics
- Foldamers3▲ 70×1 topic
- Peptide Synthesis3▲ 70×1 topic
- CAR T Cells3▲ 30×1 topic
- Chimeric Antigen Receptor3▲ 30×1 topic
- Rituximab3▲ 15×3 topics
- Tumor Regression3▲ 20×2 topics
- Molecular Docking3▲ 17×2 topics
- Monoclonal Antibody3▲ 41×2 topics
- Immune Checkpoint Blockade3▲ 18×1 topic
- PD-1 and PD-L13▲ 18×1 topic
- Gene Therapy2▲ 10×4 topics
- Genomic Profiling2▲ 19×2 topics
- Inhibitors2▲ 48×2 topics
- Prophylaxis2▲ 15×2 topics
Which research topics does Chugai Pharma (United States) publish most on?
By volume in 2022–2025: Monoclonal and Polyclonal Antibodies Research, Protein purification and stability, Chemical Synthesis and Analysis and CAR-T cell therapy research.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 9 works
- 2 Protein purification and stability Molecular Biology 4 works
- 3 Chemical Synthesis and Analysis Molecular Biology 3 works
- 4 CAR-T cell therapy research Oncology 3 works
- 5 Cancer Immunotherapy and Biomarkers Oncology 3 works
- 6 Lung Cancer Treatments and Mutations Pulmonary and Respiratory Medicine 2 works
- 7 Hemophilia Treatment and Research Hematology 2 works
- 8 Computational Drug Discovery Methods Computational Theory and Mathematics 2 works
- 9 HER2/EGFR in Cancer Research Oncology 2 works
- 10 Statistical Methods in Clinical Trials Statistics and Probability 2 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Chugai Pharma (United States)'s research output changed?
Output in 2018–2022 was 22% lower than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Berkeley Heights
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.